France · Delayed Price · Currency is EUR Valbiotis Statistics
Total Valuation
Valbiotis has a market cap or net worth of EUR 22.25 million. The enterprise value is 14.82 million.
| Market Cap | 22.25M |
| Enterprise Value | 14.82M |
Important Dates
The next estimated earnings date is Tuesday, December 29, 2026.
| Earnings Date | Dec 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Valbiotis has 35.49 million shares outstanding. The number of shares has increased by 50.00% in one year.
| Current Share Class | 35.49M |
| Shares Outstanding | 35.49M |
| Shares Change (YoY) | +50.00% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 5.23% |
| Float | 34.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.33 |
| PB Ratio | 1.74 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.58, with a Debt / Equity ratio of 0.34.
| Current Ratio | 3.58 |
| Quick Ratio | 2.85 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.14 |
Financial Efficiency
Return on equity (ROE) is -67.51% and return on invested capital (ROIC) is -29.44%.
| Return on Equity (ROE) | -67.51% |
| Return on Assets (ROA) | -25.22% |
| Return on Invested Capital (ROIC) | -29.44% |
| Return on Capital Employed (ROCE) | -52.23% |
| Weighted Average Cost of Capital (WACC) | 3.25% |
| Revenue Per Employee | 26,740 |
| Profits Per Employee | -163,840 |
| Employee Count | 50 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.74 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.50% in the last 52 weeks. The beta is -0.18, so Valbiotis's price volatility has been lower than the market average.
| Beta (5Y) | -0.18 |
| 52-Week Price Change | +4.50% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 50.25 |
| Average Volume (20 Days) | 118,964 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Valbiotis had revenue of EUR 1.34 million and -8.19 million in losses. Loss per share was -0.34.
| Revenue | 1.34M |
| Gross Profit | -704,000 |
| Operating Income | -7.99M |
| Pretax Income | -8.19M |
| Net Income | -8.19M |
| EBITDA | -7.82M |
| EBIT | -7.99M |
| Loss Per Share | -0.34 |
Balance Sheet
The company has 11.73 million in cash and 4.30 million in debt, with a net cash position of 7.43 million or 0.21 per share.
| Cash & Cash Equivalents | 11.73M |
| Total Debt | 4.30M |
| Net Cash | 7.43M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 12.52M |
| Book Value Per Share | 0.35 |
| Working Capital | 11.36M |
Cash Flow
In the last 12 months, operating cash flow was -8.87 million and capital expenditures -11,000, giving a free cash flow of -8.88 million.
| Operating Cash Flow | -8.87M |
| Capital Expenditures | -11,000 |
| Depreciation & Amortization | 169,000 |
| Net Borrowing | -1.24M |
| Free Cash Flow | -8.88M |
| FCF Per Share | -0.25 |
Margins
| Gross Margin | -52.66% |
| Operating Margin | -597.53% |
| Pretax Margin | -612.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Valbiotis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -50.00% |
| Shareholder Yield | -50.00% |
| Earnings Yield | -54.98% |
| FCF Yield | -40.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Valbiotis is 1.35, which is 115.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.35 |
| Price Target Difference | 115.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 158.87% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Valbiotis has an Altman Z-Score of 0.74 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 4 |